SCHEMBL30360615

SCHEMBL30360615

OCCc1cc(F)ccc1Br

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.36
FFAR1 O14842 1/20 0.36
FFAR4 Q5NUL3 1/20 0.36
MPO P05164 2/20 0.34
SLC6A4 P31645 2/20 0.34
DPP4 P27487 1/20 0.34
MEN1 O00255 1/20 0.33
ALDH1A1 P00352 1/20 0.33
POLB P06746 1/20 0.33
MAPT P10636 1/20 0.33
KMT2A Q03164 1/20 0.33
PLEC Q15149 1/20 0.33
NR3C1 P04150 1/20 0.33
CA3 P07451 1/20 0.32
CA6 P23280 1/20 0.32
CA5A P35218 1/20 0.32
CA9 Q16790 1/20 0.32
CA14 Q9ULX7 1/20 0.32
CA5B Q9Y2D0 1/20 0.32
HTR2A P28223 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL485871 1.00 PKM (0.36) PKMFFAR1FFAR4MPOSLC6A4
SCHEMBL17980199 0.88 CA2 (0.42) PKMFFAR1FFAR4MPOSLC6A4
SCHEMBL30817979 0.88 CA2 (0.42) PKMFFAR1FFAR4MPOSLC6A4
SCHEMBL29814990 0.83 PKM (0.40) PKMFFAR1FFAR4MPOSLC6A4
SCHEMBL3712167 0.83 PKM (0.40) PKMFFAR1FFAR4MPOSLC6A4
SCHEMBL30227514 0.83 PKM (0.38) PKMFFAR1FFAR4SLC6A4DPP4
SCHEMBL458270 0.83 PKM (0.38) PKMFFAR1FFAR4SLC6A4DPP4
Ammonia Solution, Strong SCHEMBL28943169 0.81 PKM (0.37) PKMFFAR1FFAR4SLC6A4DPP4
SCHEMBL19602322 0.81 DPP4 (0.35) PKMFFAR1FFAR4MPOSLC6A4
SCHEMBL31021710 0.80 DPP4 (0.37) PKMFFAR1FFAR4DPP4MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110088107-B Compounds, compositions and uses thereof 赛诺维信制药公司 2023-04-14 CN claimed
US-20250340516-A1 Isoquinolinones as Modulators of POLRMT PRETZEL THERAPEUTICS, INC. (US) 2025-11-06 US disclosed
EP-4540240-A1 MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME Monte Rosa Therapeutics AG (CH) 2025-04-23 EP disclosed
CN-113784755-B Salts of isochroman-based compounds, crystalline forms thereof, methods of preparation, therapeutic uses and pharmaceutical compositions 赛诺维信制药公司 2024-05-10 CN disclosed
CN-111925360-B 1-heterocyclylisochromanyl compounds and analogs for the treatment of CNS disorders 赛诺维信制药公司 2024-03-22 CN disclosed
WO-2023244815-A1 MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME MONTE ROSA THERAPEUTICS, INC. (US) 2023-12-21 WO disclosed
CN-110088107-B Compounds, compositions and uses thereof 赛诺维信制药公司 2023-04-14 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250340516-A1 Isoquinolinones as Modulators of POLRMT POLRMT, TFAM, UQCRC1 PKM 536/4885FFAR1 3309/4885FFAR4 3810/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.